<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04974528</url>
  </required_header>
  <id_info>
    <org_study_id>MKC-TI-155 Part 2</org_study_id>
    <nct_id>NCT04974528</nct_id>
  </id_info>
  <brief_title>Afrezza® INHALE-1 Study in Pediatrics</brief_title>
  <acronym>INHALE-1</acronym>
  <official_title>INHALE-1: A 26-week Primary Treatment Phase, With 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza® Versus Rapid-acting Insulin Analog Injections, Both in Combination With a Basal Insulin, in Pediatric Subjects With Type 1 or Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mannkind Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jaeb Center for Health Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mannkind Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      INHALE-1 is a Phase 3, open-label, randomized clinical study evaluating the efficacy and&#xD;
      safety of Afrezza in combination with a basal insulin (i.e., the Afrezza group) versus&#xD;
      insulin aspart or insulin lispro in combination with a basal insulin (i.e., the RAA injection&#xD;
      group) in pediatric subjects with type 1 or type 2 diabetes mellitus. Following 26 weeks of&#xD;
      randomized treatment (i.e., Afrezza or RAA injection combined with a basal insulin), all&#xD;
      subjects will enter a treatment extension where subjects will receive Afrezza until Week 52.&#xD;
      The purpose of the treatment extension is to assess safety and efficacy with continued use of&#xD;
      Afrezza.&#xD;
&#xD;
      Pediatric subjects ≥4 and &lt;18 years of age will be enrolled in this study. Subjects will be&#xD;
      randomly assigned in a 1:1 ratio to either the Afrezza group or the RAA injection group.&#xD;
&#xD;
      The study is composed of:&#xD;
&#xD;
        -  Up to 4-week screening/run-in period&#xD;
&#xD;
        -  26 week randomized treatment period&#xD;
&#xD;
        -  26-week treatment extension&#xD;
&#xD;
        -  4-week follow-up period&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c After 26 Weeks</measure>
    <time_frame>26 weeks</time_frame>
    <description>HbA1c change after 26 weeks of Afrezza compared to Rapid-Acting Analog (RAA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose (FPG) After 26 weeks</measure>
    <time_frame>26 weeks</time_frame>
    <description>FPG change after 26 weeks of Afrezza compared to Rapid-Acting Analog (RAA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Hypoglycemic Events After 26 weeks</measure>
    <time_frame>26 weeks</time_frame>
    <description>Event rate of hypoglycemia (SMBG &lt;70 mg/dL) after 26 weeks of Afrezza compared to Rapid-Acting Analog (RAA).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time in Range (70 - 180 mg/dL)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Time in Range after 26 weeks of Afrezza compared to Rapid-Acting Analog (RAA), based on continuous glucose monitoring derived glucose values.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Percent Time with Glucose &lt;54 mg/dL</measure>
    <time_frame>26 weeks</time_frame>
    <description>Percent Time with Glucose &lt;54 mg/dL after 26 weeks of Afrezza compared to Rapid-Acting Analog (RAA), based on continuous glucose monitoring derived values.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time Below Range (glucose &lt;70 mg/dL)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Time Below Range after 26 weeks of Afrezza compared to Rapid-Acting Analog (RAA), based on continuous glucose monitoring derived values.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time Above Range (glucose &gt;180 mg/dL)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Percent Time with Glucose &gt;180 mg/dL after 26 weeks of Afrezza compared to Rapid-Acting Analog (RAA), based on continuous glucose monitoring derived values.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Subjects with HbA1c &lt;7.0% at Week 26</measure>
    <time_frame>26 weeks</time_frame>
    <description>Percentage of Subjects with HbA1c &lt;7.0% after 26 weeks of Afrezza compared to Rapid-Acting Analog (RAA).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in DTSQ score After 26 Weeks of Afrezza</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) score from before the first dose of Afrezza until after 26 weeks of Afrezza therapy (Week 26 for the Afrezza arm, or Week 52 for the RAA Arm). Scores range from -18 to 18, with higher scores indicating greater treatment satisfaction.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in HbA1c During Extension - RAA arm</measure>
    <time_frame>During treatment extension at week 26 to week 52</time_frame>
    <description>Change in HbA1c from Week 26 to Week 52 for the RAA arm only (the RAA arm switches to Afrezza at Week 26)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in HbA1c After 52 Weeks - Afrezza arm</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change in HbA1c from baseline to week 52, in subjects who received Afrezza in both the randomized treatment period and the treatment extension.</description>
  </other_outcome>
  <other_outcome>
    <measure>Event Rate of Hypoglycemic Events After 52 Weeks</measure>
    <time_frame>52 weeks</time_frame>
    <description>Event rate of total, nocturnal, and severe hypoglycemic events; based on the International Society for Pediatric and Adolescent Diabetes criteria.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Hypoglycemic Events After 52 Weeks</measure>
    <time_frame>52 weeks</time_frame>
    <description>Incidence of total, nocturnal, and severe hypoglycemic events; based on the International Society for Pediatric and Adolescent Diabetes criteria.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence and Severity of Adverse Events</measure>
    <time_frame>52 weeks</time_frame>
    <description>Incidence and severity of adverse events (AEs): treatment-emergent adverse events (TEAEs), serious AEs (SAEs), and AEs of special interest (AESIs).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Percent Predicted Forced Expiratory Volume in 1 Second</measure>
    <time_frame>56 weeks</time_frame>
    <description>Change in percent predicted forced expiratory volume in 1 second (FEV1) from baseline to Weeks 13, 26, 39, 52, and 56.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Afrezza (Technosphere Insulin) + Basal Insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individualized dose of Afrezza (Technosphere Insulin) for each patient before each meal (breakfast, lunch, and dinner) for 26 weeks.&#xD;
Individualized basal insulin (insulin degludec or glargine) for each patient as 1 dose in the evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RAA Injection + Basal Insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individualized dose of RAA injection (insulin aspart or lispro) for each patient for 26 weeks.&#xD;
Individualized basal insulin (insulin degludec or glargine) for each patient as 1 dose in the evening.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Afrezza</intervention_name>
    <description>Pharmaceutical form: powder&#xD;
Route of administration: inhalation</description>
    <arm_group_label>Afrezza (Technosphere Insulin) + Basal Insulin</arm_group_label>
    <other_name>Technosphere Insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rapid-Acting Insulin Analog</intervention_name>
    <description>Pharmaceutical form: clear and colorless solution for injection&#xD;
Route of administration: subcutaneous</description>
    <arm_group_label>RAA Injection + Basal Insulin</arm_group_label>
    <other_name>insulin aspart</other_name>
    <other_name>insulin lispro</other_name>
    <other_name>Novolog</other_name>
    <other_name>Humalog U-100</other_name>
    <other_name>Admelog</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Basal Insulin</intervention_name>
    <description>Pharmaceutical form: solution for injection&#xD;
Route of administration: subcutaneous</description>
    <arm_group_label>Afrezza (Technosphere Insulin) + Basal Insulin</arm_group_label>
    <arm_group_label>RAA Injection + Basal Insulin</arm_group_label>
    <other_name>insulin glargine</other_name>
    <other_name>insulin degludec</other_name>
    <other_name>Lantus</other_name>
    <other_name>Tresiba</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Assent from the pediatric subject, as appropriate, and fully informed consent from the&#xD;
             parent(s) or legal guardian, as required by both state and federal laws and the local&#xD;
             Institutional Review Board (IRB);&#xD;
&#xD;
          -  Subjects ≥4 and &lt;18 years of age;&#xD;
&#xD;
          -  Clinical diagnosis of type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus&#xD;
             (T2DM) per the Investigator and have been using insulin for at least 6 months for&#xD;
             T1DM, or at least 3 months for T2DM&#xD;
&#xD;
          -  Treatment with basal-bolus insulin therapy delivered by multiple daily injections for&#xD;
             at least 2 weeks:&#xD;
&#xD;
          -  Acceptable bolus insulins are restricted to the RAAs insulin lispro or insulin aspart,&#xD;
             including biosimilar products.&#xD;
&#xD;
          -  Basal insulins are restricted to 100-U/mL formulations of insulin glargine or insulin&#xD;
             degludec, including biosimilar products.&#xD;
&#xD;
          -  Access to stable WiFi connection&#xD;
&#xD;
          -  HbA1c ≥7.0% and ≤11%&#xD;
&#xD;
          -  Average prandial dose of insulin ≥2 units per meal&#xD;
&#xD;
          -  Utilized continuous glucose monitor (CGM) for ≥70% of the time over a 14-day period&#xD;
             preceding randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of recent blood transfusions (within previous 3 months), hemoglobinopathies,&#xD;
             or any other conditions that affect HbA1c measurements&#xD;
&#xD;
          -  History of asthma, any other clinically important pulmonary disease (e.g., cystic&#xD;
             fibrosis or bronchopulmonary dysplasia), use of any medications to treat such&#xD;
             conditions within the last year, or significant congenital or acquired cardiopulmonary&#xD;
             disease&#xD;
&#xD;
          -  History of serious complications of diabetes (e.g., active proliferative retinopathy&#xD;
             or symptomatic autonomic neuropathy), or likely need for specific treatment for&#xD;
             diabetic retinopathy (laser photocoagulation, vitrectomy, other) in the next year.&#xD;
&#xD;
          -  FEV1 and FEV1/forced vital capacity (FVC) ≤80% of predicted Global Lung Function&#xD;
             Initiative (GLI) value&#xD;
&#xD;
          -  Inability to achieve an acceptable FEV1 and FVC reading for subjects ≥8 years of age&#xD;
             would make the subject ineligible&#xD;
&#xD;
          -  For subjects &lt;8 years of age who are unable to achieve an acceptable FVC reading, FEV1&#xD;
             only may be assessed; inability to achieve an acceptable FEV1 would make the subject&#xD;
             ineligible&#xD;
&#xD;
          -  Respiratory tract infection within 14 days before screening or between the screening&#xD;
             and randomization visits (subject may return 14 days after resolution of symptoms for&#xD;
             rescreening)&#xD;
&#xD;
          -  Inability or unwillingness to perform study procedures&#xD;
&#xD;
          -  Exposure to any investigational product(s), including drugs or devices, in the past 30&#xD;
             days&#xD;
&#xD;
          -  Any disease other than diabetes or exposure to any medication that, in the judgment of&#xD;
             the Investigator, may impact glucose metabolism, including liraglutide, and current or&#xD;
             anticipated acute uses of glucocorticoids or weight loss medications, with the&#xD;
             exception of metformin in subjects with T2DM&#xD;
&#xD;
          -  Use of antiadrenergic drugs (e.g., clonidine)&#xD;
&#xD;
          -  Any concurrent illness (other than diabetes mellitus) not controlled by a stable&#xD;
             therapeutic regimen&#xD;
&#xD;
          -  History of a significant eating disorder (e.g., anorexia or bulimia nervosa)&#xD;
&#xD;
          -  Current drug or alcohol abuse or a history of drug or alcohol abuse that, in the&#xD;
             opinion of the Investigator or the Sponsor, would make the subject an unsuitable&#xD;
             candidate for participation in the study&#xD;
&#xD;
          -  Smoking (includes cigarettes, cigars, pipes, marijuana, and vaping devices) for the&#xD;
             preceding 6 months and/or positive urine cotinine test&#xD;
&#xD;
          -  Female subject who is pregnant, breast-feeding, intends to become pregnant, or is of&#xD;
             child-bearing potential, sexually active and not using adequate contraceptive methods&#xD;
             as required by local regulation or practice&#xD;
&#xD;
          -  An event of severe hypoglycemia, as judged by the Investigator, within the last 90&#xD;
             days prior to screening&#xD;
&#xD;
          -  An episode of diabetic ketoacidosis (DKA) requiring hospitalization within the last 90&#xD;
             days prior to screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Kaiserman</last_name>
    <role>Study Director</role>
    <affiliation>Mannkind Corporation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karen Jaffe</last_name>
    <role>Study Director</role>
    <affiliation>Mannkind Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johanna Ulloa</last_name>
    <phone>818-661-5000</phone>
    <email>inhale1@mannkindcorp.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Brimberry</last_name>
      <phone>323-361-8641</phone>
    </contact>
    <contact_backup>
      <last_name>Debra Miller</last_name>
      <phone>323-361-8641</phone>
    </contact_backup>
    <investigator>
      <last_name>Roshanak Monzavi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Cintron</last_name>
      <phone>352-294-8242</phone>
    </contact>
    <investigator>
      <last_name>Michael Haller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ponja Hemphill</last_name>
      <phone>813-541-0254</phone>
    </contact>
    <investigator>
      <last_name>Henry Rodriguez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>45202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Chatila</last_name>
      <phone>317-278-8879</phone>
    </contact>
    <investigator>
      <last_name>Linda DiMeglio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julie Coffey</last_name>
      <phone>319-631-1193</phone>
    </contact>
    <investigator>
      <last_name>Michael Tansey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville Research Foundation/KCPCRU</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gwen Pierce</last_name>
      <phone>502-629-5820</phone>
    </contact>
    <investigator>
      <last_name>Kupper Wintergerst</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maureen Malloy</last_name>
      <phone>617-309-1919</phone>
    </contact>
    <investigator>
      <last_name>Lori Laffel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The DOCS</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlos Torres</last_name>
      <phone>702-785-8756</phone>
    </contact>
    <investigator>
      <last_name>Asheesh K Dewan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UBMD Pediatrics Endocrinology/Diabetes</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amanda House</last_name>
      <phone>716-323-0075</phone>
    </contact>
    <investigator>
      <last_name>Kathleen Bethin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center - Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Terri Casey</last_name>
      <phone>216-844-3627</phone>
    </contact>
    <investigator>
      <last_name>Jamie Wood</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diana Olivos-Stewart</last_name>
      <phone>267-426-9218</phone>
    </contact>
    <investigator>
      <last_name>Steven Willi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AM Diabetes and Endocrinology Center</name>
      <address>
        <city>Bartlett</city>
        <state>Tennessee</state>
        <zip>38133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lesley Draffin</last_name>
      <phone>901-531-6236</phone>
    </contact>
    <investigator>
      <last_name>Kashif Latif</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diabetes &amp; Glandular Disease Clinic</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terri Ryan</last_name>
      <phone>210-614-8612</phone>
    </contact>
    <investigator>
      <last_name>Mark Kipnes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 22, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Insulin</keyword>
  <keyword>Inhaled</keyword>
  <keyword>Afrezza</keyword>
  <keyword>Technosphere</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
    <mesh_term>Insulin, Short-Acting</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

